Wicked Good Cardiometabolic Chat: Incretin Therapies in Pediatric Obesity, T2D

Beyond the scale and numbers, the arrival of incretin therapies for children and teenagers demands a delicate balance of biological precision, empathetic counseling, and long-term metabolic monitoring.

In this month’s episode of Wicked Good Cardiometabolic Chat, hosts Hailey Choi, PharmD, BCACP, CDCES, and Jennifer Goldman, PharmD, CDCES, BC-ADM, FCCP, professors of pharmacy practice at the Massachusetts College of Pharmacy and Health Sciences, review pediatric evidence and indications for semaglutide and liraglutide, explain where tirzepatide currently fits, and distinguish approved uses from emerging applications. Two clinical cases illustrate patient selection, dosing and titration, adverse-effect management, monitoring, reproductive counseling, nutrition support, and shared decision-making.

Their discussion also addresses weight stigma, bullying, mental health, disordered eating, access barriers, and the long-term cardiometabolic consequences of pediatric obesity and youth-onset type 2 diabetes (T2D). Pharmacists can tune in for practical strategies regarding counseling young patients and their families while recognizing important evidence gaps involving growth, development, body composition, and long-term outcomes.

READ MORE: Orforglipron Shows Greater A1C, Weight Reduction Than Oral Semaglutide

Understanding Incretin Mechanisms and Distinct Pediatric Approvals

Incretin therapies function by mimicking natural intestinal hormones like glucagon-like peptide-1 (GLP-1), which enhance glucose-dependent insulin secretion, suppress glucagon release, slow gastric emptying, and promote satiety.¹

Although oral glucose normally stimulates a robust insulin response, this physiologic incretin effect is significantly diminished in individuals with T2D. Newer dual receptor agonists like tirzepatide combine GLP-1 with gastric inhibitory polypeptide action, providing enhanced glycemic control and weight reduction without delaying gastric emptying to the same extent.

In pediatric practice, pharmacists must carefully distinguish between brand names, age thresholds, and specific clinical indications. Currently in the US, injectable semaglutide (Wegovy) is indicated for obesity starting at age 12, whereas liraglutide (Saxenda) is approved for adolescent obesity at age 12 and older for patients weighing over 60 kilograms.

Conversely, T2D indications differ sharply, as Victoza and Mounjaro carry pediatric approvals for diabetes starting at age 10, but semaglutide products currently lack an approved pediatric diabetes indication. Pharmacists serve a pivotal safety role by verifying that the exact brand, patient age, and documented diagnosis align prior to dispensing.¹

Clinical Trial Evidence and Overall Pediatric Efficacy

Clinical evidence highlights substantial metabolic benefits alongside important safety parameters for pediatric patients.² In the STEP Teens trial evaluating adolescents aged 12-17, weekly semaglutide achieved a 16.1% reduction in mean body mass index compared with a 0.6% increase in the placebo arm at 68 weeks.

Broadening these findings, a comprehensive meta-analysis of 15 pediatric randomized controlled trials comprising 1286 participants demonstrated that incretin-based therapies produce a statistically significant mean weight reduction of 2.89 kilograms compared with controls. Furthermore, the meta-analysis confirmed that these therapies reduce glycated hemoglobin by 0.37% and fasting plasma glucose by 6.99 mg/dL in children with obesity, establishing GLP-1 receptor agonists as effective tools for glycemic and weight management.²

Gastrointestinal side effects such as nausea, vomiting, and occasional gallstone disorders represent the most common adverse events, yet severe hypoglycemia remains rare due to the glucose-dependent mechanism of insulin release.^1,2 Emerging trials like STEP Young are investigating semaglutide in younger children aged 6 to 11, but published data have not yet proven whether early treatment prevents long-term adult cardiovascular events or renal failure.

Practical Pharmacist Counseling, Health Equity, and Collaborative Care

Translating clinical trial evidence into community practice requires structured education, interprofessional collaboration, and compassionate patient communication.^3,4 Surveys reveal that while 73% of community pharmacists recognize obesity as a critical health issue and 67% acknowledge their management role, only 31% report formal education on weight management, signaling a need for expanded continuing education.³

Pharmacists frequently encounter structural barriers such as understaffing, time limitations, and a lack of private consultation spaces, yet systematic reviews show that 81% of successful pharmacist weight management programs utilize collaborative multidisciplinary or interdisciplinary models.^3,4

Community pharmacies remain exceptionally accessible frontline settings that help address health equity across social determinants of health, expanding care access in underserved populations.⁴ Practical counseling strategies must focus on gradual dose titration, managing gastrointestinal tolerability, and monitoring for potential nutritional deficiencies, as nearly 17% of youth initiating GLP-1 therapy develop vitamin D or other dietary deficiencies within 1 year.

Pharmacists must also offer non-judgmental support that addresses weight stigma and mental health, provide essential reproductive counseling regarding potential interactions between tirzepatide and oral contraceptives, and actively advocate for long-term health behavior support for young patients and their families.

In Wicked Good Cardiometabolic Chat, a podcast offering from Drug Topics, Goldman and Choi aim to empower pharmacists with evidence-based insights into various cardiometabolic topics. All new episodes of Wicked Good Cardiometabolic Chat will be available in a video format via DrugTopics.com on the first Wednesday of each month. Check out our most recent episode: Identifying and Managing MASH.

READ MORE: Diabetes Resource Center

REFERENCES

1. Tylee T. Incretin therapies in type 2 diabetes: clinical considerations for prescribing GLP-1 agonists. Medmastery. December 17, 2025. Accessed October 5, 2026. https://www.medmastery.com/magazine/incretin-therapies-type-2-diabetes-clinical-considerations-prescribing-glp1-agonists

2. Wang J, Kang J, Wu C, et al. The effects of incretin‐based therapies on weight reduction and metabolic parameters in children with obesity: a systematic review and meta‐analysis. Obes Rev. 2024;25(4):e13686. doi:10.1111/obr.13686

3. AlOmeir O, Almuqbil M, Alhabshi HA, et al. Exploring the role of community pharmacists in addressing obesity: a Saudi Arabian perspective. Front Public Health. 2025 Mar 10;13:1503260. doi: 10.3389/fpubh.2025.1503260

4. Sharif FV, Sharif NV, Sharif Z. Pharmacist involvement in overweight and obesity care: an equity-focused systematic review. Explor Res Clin Soc Pharm. 2026;24:100855. doi:10.1016/j.rcsop.2026.100855